Literature DB >> 1792929

Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses.

L Rampello1, G Nicoletti, R Raffaele.   

Abstract

We assessed the therapeutical efficacy of various antidepressants (amineptine, minaprine and clomipramine) in patients affected by retarded depression. All patients exhibited symptoms of retardation, including hypokinesia, anergia, reduction of speech, increased salivation, hypersomnia, Parinaud's syndrome, reduced sexual activity, slowness, hypomimia, orthostatic hypotension, dysphagia and drowsiness. Antidepressant drugs were administered for a 6-week period in a randomized double-blind vs placebo design. The rank order of clinical effectiveness (amineptine much greater than minaprine greater than clomipramine greater than placebo) paralleled the specificity of antidepressants as dopaminomimetic agents. These results support the view that a reduced dopaminergic transmission contributes to the pathophysiology of retarded depression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1792929     DOI: 10.1111/j.1600-0447.1991.tb03193.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

Review 1.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

2.  The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.

Authors:  Samantha E Yohn; Christian Thompson; Patrick A Randall; Christie A Lee; Christa E Müller; Younis Baqi; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2014-10-17       Impact factor: 4.530

3.  Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.

Authors:  Liborio Rampello; Santina Chiechio; Giovanni Nicoletti; Alessandro Alvano; Ignazio Vecchio; Rocco Raffaele; Mariano Malaguarnera
Journal:  Psychopharmacology (Berl)       Date:  2003-12-17       Impact factor: 4.530

4.  Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.

Authors:  Samantha E Yohn; Yumna Arif; Allison Haley; Guiseppe Tripodi; Younis Baqi; Christa E Müller; Noemi San Miguel; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2016-08-06       Impact factor: 4.530

Review 5.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

Review 6.  Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?

Authors:  Frank Padberg; Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Neurocognitive predictors of antidepressant clinical response.

Authors:  Gerard E Bruder; Jorge E Alvarenga; Daniel Alschuler; Karen Abraham; John G Keilp; David J Hellerstein; Jonathan W Stewart; Patrick J McGrath
Journal:  J Affect Disord       Date:  2014-05-04       Impact factor: 4.839

8.  Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.

Authors:  Eric J Nunes; Patrick A Randall; Evan E Hart; Charlotte Freeland; Samantha E Yohn; Younis Baqi; Christa E Müller; Laura López-Cruz; Mercè Correa; John D Salamone
Journal:  J Neurosci       Date:  2013-12-04       Impact factor: 6.167

9.  Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms.

Authors:  Patrick A Randall; Christie A Lee; Samantha J Podurgiel; Evan Hart; Samantha E Yohn; Myles Jones; Margaret Rowland; Laura López-Cruz; Mercè Correa; John D Salamone
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

10.  Neuropathological changes in the substantia nigra in schizophrenia but not depression.

Authors:  M R Williams; K Galvin; B O'Sullivan; C D MacDonald; E W K Ching; F Turkheimer; O D Howes; R K B Pearce; S R Hirsch; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-12-29       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.